The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
Protocol Amendment History
8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-11-06; most recent amendment 2025-12-02.
Status change: Recruiting → Active, Not Recruiting2025-09-29
Status change: Not Yet Recruiting → Recruiting2025-01-14